US00972D1054
© Globe Newswire
02.02.2026
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 132,675 shares of Akebia’s common stock on January 30, 2026. The options were gr...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 197,900 shares of Akebia’s common stock on December 31, 2025. The options were gr...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 22,576 shares of Akebia’s common stock on November 28, 2025. The options were gr...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
01.12.2025
AKBA
LISTED
NASDAQ
Q32 Bio Sells Complement Inhibitor ADX-097
News Preview
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata ---- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 ---- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments u...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Globe Newswire
01.12.2025
AKBA
LISTED
NASDAQ
Akebia Announces Establishment of Rare Kidney Disease Pipeline
News Preview
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
News Preview
Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
AKBA
LISTED
NASDAQ
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
News Preview
Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025 Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2025
AKBA
LISTED
NASDAQ
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
News Preview
Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
AKBA
LISTED
NASDAQ
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
News Preview
Presentations Detail Ongoing Vafseo® (Vadadustat) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of Vafseo Presentations Detail Ongoing Vafseo® (Vadadustat) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of Vafseo...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2025
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees options to purchase an aggregate of 204,163 shares of Akebia’s common stock on September 30, 2025. The options wer...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 95,100 shares of Akebia’s common stock on August 29, 2025. The options were gra...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.08.2025
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of Akebia’s common stock on July 31, 2025. The options were gran...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
08.07.2025
AKBA
LISTED
NASDAQ
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 137,000 shares of Akebia’s common stock on May 30, 2025. The options were gran...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2025
AKBA
LISTED
NASDAQ
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025
News Preview
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia Executive Management will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 5...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
AKBA
LISTED
NASDAQ
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
News Preview
CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of its underwritten public offering (the “Offering”) of 25,000,000 shares of its common stock at a public offe...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.03.2025
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update
News Preview
Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
AKBA
LISTED
NASDAQ
Akebia Therapeutics Announces Multiple Positive Business Updates
News Preview
New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S.
Vafseo tablets now shipping in the U.S.
Plan to start Phase 3 trial in mid-2025 to potentially expand Vafseo label to include treatment of late-stage non-dialysis CKD patients...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Jan. 2, 2025 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 3,000 shares of Akebia's common stock on December 31, 2024. The options were granted a...
Themefolio
Profiler
Peergroup
© PR Newswire
18.12.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2024...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted nine newly-hired employees options to purchase an aggregate of 121,000 shares of Akebia's common stock on November 29, 2024. The options were grant...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
AKBA
LISTED
NASDAQ
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
News Preview
Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care
CAMBRIDGE, Mass., Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that in late Novemb...
Themefolio
Profiler
Peergroup
© PR Newswire
25.11.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
News Preview
CAMBRIDGE, Mass., Nov. 25, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a Fireside Discussion at the 36th Annual Piper Sandler Healthcare Conferenc...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
AKBA
LISTED
NASDAQ
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
News Preview
Akebia continues to publish important results of FO2CUS trial to further physicians' understanding of Vafseo® (vadadustat)
CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Ameri...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference
News Preview
CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Thursday, November 21 at 1:00 PM...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
News Preview
Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for VafseoVafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System codeAkebia to Hos...
Themefolio
Profiler
Peergroup
© PR Newswire
01.11.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 20,000 shares of Akebia's common stock on October 31, 2024. The options were grante...
Themefolio
Profiler
Peergroup
© PR Newswire
01.11.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights
News Preview
Akebia to Host Conference Call on November 7, 2024, at 8:00 a.m. EST
CAMBRIDGE, Mass., Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, prior to the open of financial markets....
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
News Preview
Contract in place with a comprehensive kidney care provider serving more than 200,000 patients at its thousands of U.S. dialysis centers
CAMBRIDGE, Mass., Oct. 22, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced...
Themefolio
Profiler
Peergroup
© PR Newswire
15.10.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
News Preview
Vadadustat clinical data on display for nephrologist and healthcare providers in advance of U.S. market availability expected in January 2025
CAMBRIDGE, Mass., Oct. 15, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announ...
Themefolio
Profiler
Peergroup
© PR Newswire
10.10.2024
AKBA
LISTED
NASDAQ
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025
News Preview
Designed to help dialysis organizations incorporate new treatments into their practices, TDAPA provides two years of reimbursement in addition to the ESRD bundled rate
A HCPCS code has also been assigned to Vafseo to facilitate reimbursement at dialysis organizations
CAMBRIDGE, Mass., Oct. 10, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasd...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
News Preview
U.S. Renal Care is a leading provider of in-center and home dialysis in the United States
CAMBRIDGE, Mass., Oct. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation's fastest-growing dialysis...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Oct. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 111,600 shares of Akebia's common stock on September 30, 2024. The options were grante...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis
News Preview
Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of careTrial aims to build a body of real-world evidence to understand the potential benefits of treating patients with VafseoCAMBRIDGE, Mass., Sept. 5, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmace...
Themefolio
Profiler
Peergroup
© PR Newswire
03.09.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Sept. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 4,000 shares of Akebia's common stock on August 30, 2024. The options were granted as...
Themefolio
Profiler
Peergroup
© PR Newswire
26.08.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics to Present at Upcoming Investor Conferences
News Preview
CAMBRIDGE, Mass., Aug. 26, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 4-6, 2024 in...
Themefolio
Profiler
Peergroup
© PR Newswire
08.08.2024
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
News Preview
Vafseo® (vadadustat) Tablets market availability on track for January 2025 TDAPA application submission and WAC pricing announcement for Vafseo complete Second quarter 2024 Auryxia® (ferric citrate) net product revenues of $41.2 millionAkebia to host conference call at 8:00 a.m. ET on August 8
CAMBRIDGE, Mass., Aug. 8, 2024 /PRNewswire/ -- Akebia...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2024
AKBA
LISTED
NASDAQ
Thinking about buying stock in Akebia Therapeutics, Mind Medicine, ATAI Life Sciences, Doma Holdings, or Iterum Therapeutics?
News Preview
NEW YORK, April 1, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKBA, MNMD, ATAI, DOMA, and ITRM.
To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObser...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
